Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. (PRPH) generates a steady flow of company news across biotech, genomics, and consumer health. Its press releases and regulatory disclosures cover developments in molecular diagnostics, whole genome sequencing, OTC dietary supplements, capital markets activity, and strategic initiatives. For investors and followers of PRPH, this news stream provides insight into how the company is advancing its programs and managing its capital structure.
A major news theme for ProPhase is the BE-Smart Esophageal Cancer Test. Company announcements describe peer-reviewed validation studies conducted with Mayo Clinic, publication in leading gastroenterology journals, and plans for commercialization and clinical integration. Updates often detail BE-Smart’s performance metrics, its role in Barrett’s Esophagus risk stratification, and steps toward broader adoption and reimbursement discussions.
Another recurring topic is genomics and Nebula Genomics. ProPhase’s news highlights its whole genome sequencing offerings and the positioning of Nebula Genomics as a consumer genomics platform with a large and diverse DNA dataset. Releases also discuss related consumer health initiatives, including DNA Complete and DNA Expand product lines, within the company’s genomics and wellness strategy.
Capital structure and financing updates are also prominent in PRPH news. Recent items include information on senior secured convertible notes and warrants registered via an S-1, an at-the-market sales agreement, a 1-for-10 reverse stock split to address listing requirements, and shareholder communications about trading activity, convertible debt conversions, and the transition from Nasdaq to the OTC market. These disclosures explain how ProPhase is addressing liquidity, managing dilution, and aligning its share structure with strategic goals.
Strategic and legal developments appear as well, such as a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S.A., the Crown Medical Collections receivables recovery initiative, and updates on legal matters disclosed in Form 8-K filings. For readers tracking PRPH, this news page aggregates these diverse updates in one place, making it easier to follow the company’s diagnostics, genomics, consumer health, and corporate actions over time.
ProPhase Labs (NASDAQ: PRPH) announced publication of a peer‑reviewed study in Clinical and Translational Gastroenterology validating BE‑Smart, an 8‑protein, mass‑spectrometry proteomic assay for risk stratification in Barrett’s Esophagus. Key clinical findings include 100% sensitivity for patients who later developed esophageal adenocarcinoma, overall AUC 0.75, independent test cohort AUC 0.89, and AUC 1.0 for progressors within three years. The study reports a hazard ratio 66.1 (p=0.00012) for high‑risk vs low‑risk patients. BE‑Smart requires as little as one‑tenth the tissue of legacy assays and works on standard formalin‑fixed, forceps or brush biopsy samples. Early access and physician onboarding are expected in early 2026.
ProPhase Labs (NASDAQ: PRPH) engaged RedChip Companies on October 28, 2025 to lead investor relations as the company advances commercialization and recovery initiatives. Key company priorities cited include the imminent commercialization of BE-Smart™ (esophageal cancer diagnostic), expansion of the Nebula Genomics platform, and the Crown Medical Collections initiative targeting over $50 million in near-term recoveries. RedChip will use digital distribution, webinars, roadshows, and its Small Stocks, Big Money™ program; Renmark will continue hosting quarterly earnings calls and retail virtual non-deal roadshows.
ProPhase Labs (NASDAQ: PRPH) will participate in the ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental Hotel in New York.
Ted Karkus, CEO and Chairman, will present at 11:00 AM ET on October 30 and will hold one-on-one investor meetings throughout the day. Interested investors can register and schedule meetings via the provided registration link, and the presentation will be live-streamed at the supplied webcast URL.
ProPhase Labs (NASDAQ: PRPH) announced that a pivotal study validating the BE-Smart esophageal cancer proteomic test was accepted for publication in Clinical Gastroenterology and Hepatology on October 22, 2025. The study reported 100% sensitivity in a blinded cohort of 100 patients and strong discriminative performance (AUC 0.89–1.0) in independent test cohorts. ProPhase is advancing regulatory preparations, scaling laboratory capacity, and planning a phased commercial rollout beginning in 2026. Management cites a U.S. addressable market of roughly $7–$14 billion tied to ~7 million annual upper endoscopies for GERD and BE surveillance.
ProPhase Labs (NASDAQ: PRPH) announced that its three COVID-19 testing laboratory subsidiaries have filed for Chapter 11 bankruptcy reorganization. This strategic move is part of the Crown Medical Collections initiative to recover an estimated $50 million in unpaid claims from insurance companies.
The bankruptcy filing is limited to the COVID-19 lab testing units and does not affect the parent company or other subsidiaries. Crown Medical anticipates potential Q4 collections that could be multiples of the company's current market capitalization. The company continues to advance other initiatives, including the development of the BE-Smart™ esophageal cancer test, and operations at Nebula Genomics and DNA Complete subsidiaries.
ProPhase Labs (NASDAQ: PRPH) announced its continued exploration of a crypto treasury strategy following stockholder approval at the September 9 Special Meeting. The company has entered into an agreement for potential advisory services to evaluate balance sheet resource allocation options, including digital asset investments.
CEO Ted Karkus highlighted that the company recently cancelled its Equity Line of Credit (ELOC) to avoid dilutive financing, citing significant underlying company value. Additionally, ProPhase anticipates updates on its Crown Medical Collections initiatives, which could generate $50 million in cash, and developments in its BE-Smart™ Esophageal cancer test.
ProPhase Labs (NASDAQ: PRPH) announced strong stockholder support at its Special Meeting on September 9, 2025, with all proposals receiving over 75% approval. A key approval includes increasing authorized shares to 1 billion, enabling the company to pursue strategic initiatives including a crypto treasury strategy.
The meeting success follows the June annual meeting where Board members were re-elected with over 90% support. The company also anticipates updates on its Crown Medical Collections initiative, targeting up to $50 million in Covid accounts receivables, and developments in the commercialization of its BE-Smart Esophageal Cancer Test.
ProPhase Labs Inc. (NASDAQ: PRPH) announced its participation in Renmark Financial Communications' Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025, at 12:00 pm EDT. The presentation will feature CEO Ted Karkus discussing the company's overview and key initiatives, including their crypto treasury strategy and potential liquidity events.
Notably, the company has announced the cancellation of their Equity Line of Credit (ELOC). The event will include a live Q&A session, with registration required for attendance. While live participation may be limited, a replay will be available on the company's investor website.
ProPhase Labs (NASDAQ: PRPH) has filed its definitive proxy statement and rescheduled its Special Meeting of Shareholders to September 9, 2025. The company is seeking shareholder approval for several strategic initiatives, including a significant increase in authorized shares from 50 million to 1 billion, a $15 million share repurchase program, and the implementation of a crypto treasury strategy involving Bitcoin investments.
The company aims to leverage potential liquidity events, including a possible $50 million from Crown Medical Collections and the potential sale of Nebula Genomics, to fund its crypto treasury strategy. Management emphasizes these initiatives are designed to support the commercialization of the BE-Smart™ Esophageal Cancer test and grow the restructured Nebula Genomics subsidiary, which is projected to be profitable on a pro forma basis.
ProPhase Labs (NASDAQ: PRPH) reported financial results for Q2 2025, highlighting significant operational improvements and strategic initiatives. The company secured a key patent for its BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test and strengthened its equity position to $11.5 million from $7.4 million at 2024 year-end.
Key financial metrics show Q2 2025 net revenue of $1.2 million with improved gross margins of 58.9% compared to -10.3% in Q2 2024. Operating expenses were reduced by over 35% YTD. The net loss narrowed to $4.5 million ($0.11 per share) from $5.5 million ($0.29 per share) in Q2 2024.
Strategic developments include potential recovery of $50 million through Crown Medical Collections, streamlining of Nebula Genomics operations to break-even, and a new crypto treasury initiative involving Bitcoin acquisition. The company also completed strategic divestitures generating an $8.7 million gain and eliminating over $20 million in debt/liabilities.